Is PSA Still the Best Predictor for Biochemical Recurrence after Radical Prostatectomy in High-Risk Prostate Cancer?

References

• D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974.
   PubMed Web of Science ®Google Scholar
• Knipper S, Karakiewicz PI, Heinze A, et al. Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy. Urol Oncol. 2020;38(4):184–190. doi:10.1016/j.urolonc.2019.12.014.
   PubMed Web of Science ®Google Scholar
• Boehm K, Leyh-Bannurah S-R, Rosenbaum C, et al. Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy. BJU Int. 2017;120(5):666–672. doi:10.1111/bju.13887.
   PubMed Web of Science ®Google Scholar
• Devos G, Devlies W, De Meerleer G, et al. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol. 2021;18(12):739–762. doi:10.1038/s41585-021-00514-9.
   PubMed Web of Science ®Google Scholar
• Mottet N, Cornford P, van den Bergh RCN, et al. EAU guidelines: prostate cancer. Arnhem, The Netherlands: European Association of Urology; 2021. https://uroweb.org/guideline/prostate-cancer/
   Google Scholar
• Sahin H, Deliktas H. Radical prostatectomy and lymphadenectomy in the high-risk prostate cancer: surgical technique, functional and oncologic outcomes. Bull Urooncol. 2015;14:113–119.
   Google Scholar
• Yossepowitch O, Eggener SE, Bianco FJ, Jr, et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007;178(2):493–499. doi:10.1016/j.juro.2007.03.105.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Bianco FJ, Jr, Kuroiwa K, et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol. 2006;176(3):991–995. doi:10.1016/j.juro.2006.04.048.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–2027. doi:10.1016/S0140-6736(12)61253-7.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading Committee. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–252. doi:10.1097/PAS.0000000000000530.
   PubMed Web of Science ®Google Scholar
• Mossanen M, Nepple KG, Grubb RL, et al. Heterogeneity in definitions of high-risk prostate can-cer and varying impact on mortality rates after radical prostatectomy. Eur Urol Oncol. 2018;1(2):143–148. doi:10.1016/j.euo.2018.02.004.
   PubMed Web of Science ®Google Scholar
• Briganti A, Joniau S, Gontero P, et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol. 2012;61(3):584–592. doi:10.1016/j.eururo.2011.11.043.
   PubMed Web of Science ®Google Scholar
• Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008;53(5):950–959. doi:10.1016/j.eururo.2007.10.008.
   PubMed Web of Science ®Google Scholar
• Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751–756. doi:10.1111/j.1464-410X.2005.05394.x.
   PubMed Web of Science ®Google Scholar
• Berglund RK, Jones JS, Ulchaker JC, et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology. 2006;67(6):1253–1256. doi:10.1016/j.urology.2005.12.003.
   PubMed Web of Science ®Google Scholar
• Loeb S, Schaeffer EM, Trock BJ, et al. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 2010;76(3):710–714. doi:10.1016/j.urology.2009.09.014.
   PubMed Web of Science ®Google Scholar
• Lewinshtein D, Teng B, Valencia A, et al. The long-term outcomes after radical prostatectomy of patients with pathologic Gleason 8 − 10 disease. Adv Urol. 2012;2012:428098. doi:10.1155/2012/428098.
   PubMedGoogle Scholar
• Stewart SB, Boorjian SA. Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo clinic perspective. Urol Oncol. 2015;33(5):235–244. doi:10.1016/j.urolonc.2014.10.003.
   PubMed Web of Science ®Google Scholar
• Pérez JL, Puente ET, Kulich EI, et al. Relationship between tumor grade and geometrical complexity in prostate cancer. bioRxiv. 2015;15016. doi:10.1101/015016.
   Google Scholar
• Capitanio U, Karakiewicz PI, Valiquette L, et al. Biopsy core number represents one of foremost predictors of clinically significant Gleason sum upgrading in patients with low-risk prostate cancer. Urology. 2009;73(5):1087–1091. doi:10.1016/j.urology.2008.10.048.
   PubMed Web of Science ®Google Scholar
• Harbin AC, Eun DD. The role of extended pelvic lymphadenectomy with radical prostatectomy for high-risk prostate cancer. Urol Oncol. 2015;33(5):208–216. doi:10.1016/j.urolonc.2014.11.011.
   PubMed Web of Science ®Google Scholar
• Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, et al. Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review. Eur Urol. 2020;77(5):614–627. doi:10.1016/j.eururo.2020.01.033.
   PubMed Web of Science ®Google Scholar